John P. Carulli

Cystic Fibrosis Foundation — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

32h-index7.4kcitations76works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Research and Splicing(8), Rheumatoid Arthritis Research and Therapies(7), Genomics and Chromatin Dynamics(6), Cancer-related Molecular Pathways(6), Monoclonal and Polyclonal Antibodies Research(6)

Publications75 total

Upregulation of a CFTR mRNA isoform has therapeutic potential for the treatment of 3′ CFTR PTC variants
Molecular Therapy — Nucleic Acids·2026Open Access
247 Targeted gene insertion for functional CFTR restoration in cystic fibrosis airway epithelium
Journal of Cystic Fibrosis·2025
327 Are there liabilities of codon optimization: assessment of codon optimization methods in primary Human Bronchial Epithelial (hBE)
Journal of Cystic Fibrosis·2025
233 Therapeutic transgenes need optimization - Dissecting factors that affect CFTR super exon performance
Journal of Cystic Fibrosis·2025
267 Genome-wide KO Screen (GWS) to uncover genes promoting premature termination codon readthrough
Journal of Cystic Fibrosis·2025
308 MRT-2359 - a novel molecular glue degrader of eRF3a induces readthrough of CFTR PTC variants
Journal of Cystic Fibrosis·2025
263 In vitro evaluation of commonly used airway cell type specific promoters: Foxj1 for Ciliated, SCGB1A1/CCSP for Secretory/Club and Keratin 5 for Basal cells
Journal of Cystic Fibrosis·2025
234 CF-specific cell lines, plasmids, and other research tools are available from the CFFT Lab
Journal of Cystic Fibrosis·2025
252 Model systems to define tool LNP vehicles for the development of next generation therapies for Cystic Fibrosis
Journal of Cystic Fibrosis·2025
TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network
Science Advances·2025· 6 citedOpen Access
278 Examining variation in intron 1 of CFTR relative to self-reported and genomic defined race
Journal of Cystic Fibrosis·2024
PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY
HemaSphere·2023Open Access
Erythroid lineage chromatin accessibility maps facilitate identification and validation of NFIX as a fetal hemoglobin repressor
Communications Biology·2023· 11 citedOpen Access
Targeting <i>RARA</i> overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
Blood Advances·2022· 33 citedOpen Access
ΔNp63/p73 drive metastatic colonization by controlling a regenerative epithelial stem cell program in quasi-mesenchymal cancer stem cells
Developmental Cell·2022· 32 citedOpen Access
Abstract 5393: An oral and selective CDK12 inhibitor demonstrates robust anti-tumor activity
Cancer Research·2022
ITC-Asia 2021 Cover Page
2021Open Access
Abstract P4-04-02: Epigenomic analysis of cancer stem cells (CSCs) from triple-negative breast cancer (TNBC) reveals p63 and p73 as core metastasis drivers
Cancer Research·2020
Chromatin Accessibility Mapping of Primary Erythroid Cell Populations Leads to Identification and Validation of Nuclear Factor I X (NFIX) As a Novel Fetal Hemoglobin (HbF) Repressor
Blood·2019· 3 cited
Abstract 4409: Prospective identification of RB pathway alterations predict response to SY-1365, a selective CDK7 inhibitor, in a panel of high-grade serous ovarian cancer (HGSOC) patient derived xenograft (PDX) models
Molecular and Cellular Biology / Genetics·2019· 1 cited
page 1 of 4Next →

Frequent Co-authors

Norm Allaire(8), Chao Sun(7), Peter K. Gregersen(6), Wentian Li(5), Daniel L. Hartl(5), Jadwiga Biénkowska(5), Robert M. Plenge(4), Franak Batliwalla(4), John F. Staropoli(4), Cleona R. Allen(4), Cathy S.J. Fann(4), Kathleen Falls(4), Tim P. Keith(4), Pamela Swain(3), Linda Chee(3), Craig Tulig(3), Peter T. Lomedico(3), Josée Dupuis(3), Mark A. Osborne(3), Elaine F. Remmers(3)